TICKER: BLU:TSX; BLUSF:OTCPK
BELLUS Health Inc. is a drug development company focused on rare diseases. Based in Laval, Quebec, the company has a portfolio of rare disease projects including KIACTA for AA amyloidosis (an orphan indication resulting in renal dysfunction that often rapidly leads to dialysis and death), clinical-stage Shigamab for Shiga toxin-producing Escherichia coli-related hemolytic uremic syndrome, and a research-stage project for AL amyloidosis. Its lead program, KIACTA, is partnered with global private equity firm Auven Therapeutics LLLP and is currently in phase 3 confirmation study.
The information provided below is from analysts, newsletters and other contributors. Please contact the company and visit its website before making an investment decision.
Due to permission requirements, not all quotes are shown.
BELLUS Health Inc. Content
Back to Top